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Aim: The aim of this study was to examine the cooccurrence of heightened media
attention after the publication of a paper by Skovlund et al in September 2016 on
the link between hormonal contraception and depression or mood on adverse drug
reaction (ADR) reports in the UK.
Methods: A quantitative analysis of relevant newspaper articles published between
January 2014 and December 2017 was performed, as well as a content analysis.
ADR reports were collected from the Medicines and Healthcare Products Regulatory
Agency website and via a Freedom of Information request. A quantitative analysis
was performed on ADR reports of hormonal contraceptives for all ADRs and for
depressed mood disorders and disturbances.
Results: The publication of the Skovlund et al paper did not lead to a peak in relevant
newspaper articles, but there was a change in the content of the newspaper articles,
which focussed more on the link between hormonal contraceptives and depression or
mood. There was an overall increase in ADR reports by women relating to hormonal
contraceptives between 2016 and 2017, and for combined contraceptives this was
due to an increase in ADR reports of depressed mood disorders and disturbances.
Conclusions: The content of media attention appears to affect ADR reporting by
women for combined contraceptives. In general, patients report the majority of
depressed mood disorders and disturbances ADRs as opposed to health profes-
sionals, who report other ADRs. Care providers can anticipate the effect of
heightened media attention and help patients when they experience these ADRs.
K E YWORD S
adverse drug reaction reporting systems, depressive disorder, drug-related side effects and
adverse reactions, hormonal contraception, mass media, pharmacovigilance
1 | INTRODUCTION
On 28 September 2016, a study by Skovlund et al entitled “Association
of hormonal contraception with depression” was published in JAMA
Psychiatry.1 The findings were widely covered in the UK media, and it
seems reasonable to ask if this media coverage could, in turn, have
impacted on the behaviour of users of hormonal contraceptives, spe-
cifically on spontaneous adverse drug reaction (ADR) reporting.
Depression and/or mood changes have been associated with the
use of hormonal contraceptives for some time, with oestrogen and
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progesterone both hypothesised to influence women's mental
health.2,3 However, it is accurate to say that, while summaries of
product characteristics and the respective patient information leaflets
of hormonal contraceptives have listed depression and mood distur-
bances as possible side effects for some time, the Skovlund et al paper
was significant because it showed a scientific association between the
use of such products and subsequent antidepressant use and first
diagnosis of depression.1
In the UK, the Yellow Card Scheme (YCS), operated by the medi-
cines regulator, the Medicines and Healthcare Products Regulatory
Agency (MHRA), provides a process for collecting suspected ADR
reports following the use of a medicine, vaccine or herbal or comple-
mentary remedy. Reports received are evaluated to identify new
potential hazards or new information on known ADRs, resulting in
changes to summaries of product characteristics and patient informa-
tion leaflets, including to the recommended dose or even the with-
drawal of a medicine, where appropriate.4 Founded in 1964 after the
thalidomide tragedy, the scheme was extended beyond health
professionals to include patients and their representatives in 2005.
Collecting these spontaneous reports sits within the field of
pharmacovigilance and surveillance monitoring, which also
encompasses anecdotal reports, observational studies, clinical trials,
systematic reviews or even animal data.5 Indeed, the Skovlund et al
paper1 itself, as an observational cohort study of prescribing registers,
is a type of surveillance monitoring. The question is whether people's
enhanced awareness of an ADR from one type of pharmacovigilance
activity (ie, observational investigation), albeit via heightened media
coverage, can impact on another, namely spontaneous reporting via
the Yellow Card Scheme.
This question is important for two reasons. First, patient reports
have been shown to strengthen ADR signal detection, while also
highlighting the patient experience and perspective,5 and are therefore
to be encouraged. Second, while patients do now form the highest
group reporting directly via the Yellow Card Scheme compared to any
specific health professional group, 2018 saw a general decline in the
reporting of suspected ADRs from other key reported groups such as
general practitioners, pharmacists and hospital doctors. Understanding
influences on suspected ADR reporting could then conceivably also
help tackle potential under-reporting (as well as helping maintain
patient reporting). Martin et al, asking a similar question, examined the
impact of intense media scrutiny regarding paroxetine and suicidal
behaviour on the subsequent prescribing of the drug and suspected
ADR reports between 2001 and 2004 in England.6 Their analysis of
national prescribing trends and Yellow Card Scheme reports for the
wider drug class of selective serotonin reuptake inhibitors (SSRIs)
linked the media publicity with an increase in ADR reports for paroxe-
tine, albeit in sharp and short-term peaks.6 There was also a fall in SSRI
prescribing after regulatory agencies in both the USA and the UK
exposed the problem.6 In 2012, Hernandez et al also showed changes
in SSRI usage to be associated with the timing of media coverage and
regulatory warnings about them in both the Netherlands and the UK.7
Thus, certainly behaviours around SSRIs appear to be influenced by
mass communication about them. Statins, a different type of drug,
have also received heightened negative media coverage. Van Hunsel
et al's paper examined the after-effects of the broadcast of a Dutch
television programme, Radar, covering serious ADRs experienced by
people taking statins, finding a peak in patient-reported (but not
health-professional-reported) ADRs in the succeeding 3 months.8
The media have has a great effect on what the mass audience
thinks about important issues, such as health. There are several
models to describe the effects of the media on public perception.
Agenda setting is an example in which the media influence determines
the importance of news for the public. When the media put more
emphasis on a certain subject (eg, hormonal contraception and
depression), it becomes more important to the public.9 Where agenda
setting shows an effect on what people are talking about, the model
of framing suggests that the media can influence the feelings of
people on an issue.10 The frames used in a news story will predict the
way in which the public reacts, eg, resulting in heightened reporting
of ADRs after media attention.11
The general public is mainly informed on health news by the
media, with newspaper articles being the key source for health infor-
mation.12 In recent years, social media platforms such as Facebook
and Twitter have become popular too, especially among adults aged
18-29.13 Health information is also available on these online
platforms. However, a study by Mollema et al shows that traditional
media predominantly determine what is said online, and that online
and offline articles show a similar distribution of articles.14
In 2015, 81.3% of women in the UK used a form of contraception
compared to 69.2% in Europe, with the majority using oral hormonal
What is already known about this subject
• People's usage of selective serotonin reuptake inhibitors
and statins, and ADR reporting behaviours have
previously altered following media sensationalising.
• Use of hormonal contraception has been linked to
depression and mood changes.
• The cooccurrence of heightened media attention and the
reporting of hormonal contraception ADRs, after a major
study, remained unknown.
What this study adds
• The content, rather than the quantity, of newspaper
articles has an effect on patient ADR reporting.
• Heightened media attention, predominantly, had an
effect on ADR reports of combined hormonal
contraceptives.
• Women report the majority of ADRs for hormonal
contraception within the category “depressed mood dis-
orders and disturbances”.
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contraceptive pills.15 While there was intense media coverage of hor-
monal contraception and its effects on depression and mood changes
after the publication of the Skovlund et al paper,1 the cooccurrence of
this media attention and changes in prescription numbers and ADR
reports remains unexamined. The aim of this study was to examine
the cooccurrence of media reporting, of the link between hormonal
contraception and depression or mood changes, and Yellow Card
Scheme reports submitted in the UK between 2014 and 2017 to
encompass at least a year before and after the publication of the
Skovlund et al1 paper in September 2016.
2 | METHODS
2.1 | Data collection
2.1.1 | Newspaper articles
The Times, The Guardian, The Telegraph, The Independent, The Sun, the
Daily Mirror, the Daily Express, the Daily Star and the Daily Mail, includ-
ing their Sunday and online editions, were searched because of their
status as the most circulated newspapers in the UK.16,17 The data-
bases ProQuest, using the search terms (depress*) AND (“the pill” OR
contracepti* OR “birth control”), and LexisNexis, using the search
terms (depress! OR mood!) AND (“the pill” OR contracepti* OR “birth
control”), were used to extract all newspaper articles published
between January 2014 and December 2017. A time period before the
publication of the Skovlund et al paper in September 2016 was cho-
sen to show the usual media coverage of the link between hormonal
contraception and depression. A shorter study period was chosen
after September 2016 to explore changes in coverage because
previous studies have shown a short maintenance stage after the
publication of key papers in which media coverage peaks and stays
constant.9,11,18
The selected articles were read by LP and judged on relevance.
Articles were considered relevant if a concrete link between hormonal
contraception and depression or mood alterations was mentioned
(eg, “The drugs [birth control] … are known to have side-effects in
some adults, including nausea, depression, acne and headaches.”
[Daily Express, 2014]). Articles were excluded when considered irrele-
vant (eg, if the search terms were mentioned in the article, but dis-
cussed separately) or when depress*, mood! or “the pill” were used in
a different context unrelated to the research question. The relevance
of the selected newspaper articles was double-checked by PD. The
inclusions and exclusion decisions were discussed between the two
researchers to reach a consensus.
2.1.2 | Prescription items
Monthly data on the number of combined hormonal contraceptives/
systems encompassing nine different formulations (British National
Formulary [BNF] legacy, 7.3.1 drug class) and progestogen-only
contraceptives encompassing nine other formulations (BNF 7.3.2
drug class), prescribed between January 2014 and December 2017,
were extracted from OpenPrescribing.net19 and maintained within an
Excel spreadsheet.
2.1.3 | ADR reports
Suspected ADR reports made for hormonal contraceptives for the
period 2014 to 2017 were extracted manually from the MHRA inter-
active Drug Analysis Profiles (iDAPs) on the Yellow Card website.4
The total yearly number of suspected reactions and the number
classed within the subset high level group term (HLGT) Depressed
mood disorders and disturbances (encompassing Depressive disorders
and Mood alterations with depressive symptoms) for each of 14 drug
substances were extracted and recorded in Excel. Additional informa-
tion (labelled type 1B data by the MHRA) on patient sex, age group,
ADR reporter (woman or healthcare professional [HCP]), report
submission route (direct to agency or indirect via industry), route of
drug administration and ADR seriousness for the yearly reports was
available and additionally retrieved.
Individual data points for estradiol, ethinylestradiol and
mestranol were added together to create total reports for the
combined contraceptives category. In the UK, combined oral
contraceptives also contain a progestogen, therefore if a suspected
ADR report is submitted for, say, the drug Logynon (which contains
both ethinylestradiol and levonorgestrel), this is recorded twice on
iDAPs under each constituent substance. Therefore, to eliminate
double-counting, the total number of suspected reactions for
progestogen-only contraceptives was derived by first adding together
the number of reports for each of the 11 relevant substances
(medroxyprogesterone acetate, norgestimate, norethisterone,
norelgestromin, nomegestrol, levonorgestrel, gestodene,
etonogestrel, drospirenone, dienogest, desogestrel) then subtracting
the respective number for the combined contraceptives.
The relevant monthly data were obtained via a Freedom of Infor-
mation request to the MHRA. Suspected ADR reports were
chronicled according to the drug substance. Type 1B data for monthly
ADR reports are not provided by the MHRA.
2.1.4 | Inclusion and exclusion criteria
Inclusion criteria for yearly suspected ADR reports were (a) women,
(b) age groups 10-19 to 50-59, (c) reporter patient or HCP, (d) direct
to agency (ie, reported directly to the MHRA), (e) all routes of adminis-
tration, (f) all types of seriousness, (g) all suspected ADR reports and
Depressed mood disorders and disturbances and (h) year received 2014
to 2017.
The oestrogens estradiol and ethinylestradiol can be given as
monotherapy for indications other than contraception and therefore
only suspected ADR reports for multiple active constituents of
these oestrogens were included.20,21 Suspected ADR reports of oral
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single constituents of levonorgestrel were excluded because these are
used as emergency contraception.22 The routes of administration that
were included for medroxyprogesterone were subcutaneous, intra-
muscular and parenteral because these routes are used for the pur-
pose of contraception.23 The active substances norethisterone and
drosperinone also have other indications than contraception, but
these could not be excluded.24–26
Although cyproterone acetate (Dianette) functions as a contra-
ceptive pill, it is not licensed as a contraceptive in the UK and is only
mentioned in BNF chapter 13.6.2. “Oral Preparations of Acne” of the
BNF legacy,22,23 so it was excluded from this study.
2.2 | Data analysis
2.2.1 | Newspaper articles
Quantification of relevant newspaper articles
The numbers of relevant articles appearing in the 4-month period
September-December (in 2016, being the months directly ensuing the
publication of the Skovlund et al paper1) for each of the 4 years
2014-2017 were compared using a one-way ANOVA test. The total
numbers of relevant articles per year were also compared.
Content analysis of relevant newspaper articles
The frequency with which relevant newspaper articles appear on their
own is not fully informative about the actual messages carried. For
that reason, a quantitative content analysis was used to examine dif-
ferences in headlines and content of relevant newspaper articles
before and after September 2016. A coding frame was constructed by
one author (LP) after scrutinising a subset of 14 randomly selected rel-
evant newspaper articles to create thematic categories, shown in
Table 1. Then PD coded the same 14 randomly selected newspaper
articles using the categories, after which the inter-rater reliability was
determined using Cohen's kappa. Then, the whole set of relevant
newspaper articles was read and coded by LP in consultation with
PD. Finally, χ2 tests were used to examine specific differences
between the newspaper articles published before and after
September 2016 in the identified categories as detailed in the results.
Prescription items and ADR reports: Statistical analysis
Monthly prescription data for combined contraceptives and
progestogen-only contraceptives between January 2014 and
December 2017 were analysed to assess correlation using a
Spearman's Rho. Because the number of prescriptions for combined
contraceptives decreased between 2014 and 2017 (rs = −0.740,
P < 0.01), and prescriptions for progestogen-only contraceptives
increased over the same period (rs = 0.641, P < 0.01) (Figure 1), ADR
reports were corrected for the respective number of prescription
items by expressing the number of reports/100 000 000 items.
The monthly number of ADR reports/100 000 000 items for
HLGT Depressed mood disorders and disturbances for combined contra-
ceptives and progestogen-only contraceptives were compared to
examine for differences before and after publication of the Skovlund
et al paper in 2016, as follows.1 ADR reports/100 000 000 items from
September 2016-December 2016 and January 2017-April 2017
(accounting for a lag time) were compared to these same months in
2014, 2015, 2016 and 2017, respectively. A one-way ANOVA with
Bonferroni post hoc test was used to determine any differences.
Spearman's Rho was used to assess the correlation of monthly ADR
reports/100 000 000 items between September 2016 and April 2017.
To test if media attention affected the number of woman-
submitted ADR reports, χ2 tests were used to examine differences in
ADR reports/100 000 000 items for woman- versus HCP-submitted
reports in 2016 versus 2017.
SPSS 24.0 was used for the statistical analyses (IBM Corp. in
Armonk, NY, USA), and statistical significance was set at P < 0.05.
2.2.2 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to
PHARMACOLOGY.
3 | RESULTS
3.1 | Newspaper articles
3.1.1 | Identification of newspaper articles
A total of 987 newspaper articles, published between 1 January 2014
and 31 December 2017, was initially identified using the aforemen-
tioned search terms (Figure 2). From these, 891 articles were excluded
and 96 articles were deemed relevant. Articles were mainly excluded
because the search terms were mentioned within, but not
linked together. The relevant articles were divided into two groups:
appearing before publication of the Skovlund et al paper1 in
September 2016 (n = 41) or appearing after its publication (n = 55).
3.1.2 | Quantification of relevant newspaper
articles
During September-December 2016, the 4 months after publication of
the Skovlund et al paper, a total of 31 relevant newspaper articles
were written (Figure 3).1
There was a statistically significant difference between this figure
and the total number of relevant articles published in these same
months in the other years, namely 2014, 2015 and 2017 (F(3,
15) = 5.893, 0.010). However, Levene's test indicated violation of the
assumption of homogeneity (P < 0.05) and therefore the Games-
Howell test was used as post hoc test to locate the difference. These
comparisons showed no statistically significant difference between
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the mean of relevant articles published in September-December 2016
and the same 4 months of 2014, 2015 and 2017.
The total number of relevant newspaper articles published per
year in each of 2014-2017 was also not significantly different (F(3,
47) = 0.885, 0.456).
3.1.3 | Analysis of newspaper content
The headlines of the relevant newspaper articles were more likely to
mention both contraception and depression or mood after September
2016 (n = 19, 34.5%) compared to before September 2016 (n = 1,
2.4%) ( χ2 (1) = 36.1113, P < 0.01) (see Table 1). Before September
2016, the retrieved newspaper articles mostly mentioned
contraception only in the headlines.
The articles themselves were also more likely to focus specifically
on associating contraception and depression or mood after September
2016 (n = 21, 38.2%) compared to before September 2016 (n = 2,
4.9%) ( χ2 (1) = 30.061, P < 0.01). Note. While articles were only
included in the study if they mentioned both, this was no guarantee
of a focus on linking the two. Articles, whether written before or after
the Skovlund et al paper,1 mostly mentioned hormonal contraception
or oral contraception (versus, eg, implants) when associating the drug
with the ADR, which was more likely to be referred to using the word
“depression” after September 2016 (n = 44, 80.0%) compared to
before September 2016 (n = 25, 61.0%) ( χ2 (1) = 7.796, P < 0.01).
In addition, the way in which the association between contracep-
tion and depression or mood was made changed so that it was less
likely for this to be a standalone statement after September 2016
(n = 15, 27.3%) compared to before September 2016 (n = 26, 63.4%)




2016 (n = 41)
After September
2016 (n = 55)
n % n % n % χ2 (before vs after)
Search terms mentioned in the headline of the newspaper article
None 22 22.9 11 26.8 11 20.0 0.243
Contraception 53 55.2 28 68.3 25 45.5 0.001**
Depression/mood 1 1.0 1 2.4 0 0.0 0.497a
Both 20 20.8 1 2.4 19 34.5 0.000**
Theme of the newspaper article
Acne treatment 7 7.3 5 12.2 2 3.6 0.027*
Male contraception 12 12.5 1 2.4 11 20.0 0.000**
Female contraception 29 30.2 18 43.9 11 20.0 0.000**
Blood clots 4 4.2 3 7.3 1 1.8 0.093a
Contraceptive app/natural contraception 12 12.5 6 14.6 6 10.9 0.318
Contraception and depression/mood 23 24.0 2 4.9 21 38.2 0.000**
Other 12 12.5 6 14.6 6 10.9 0.318
Contraception method mentioned in the link
Hormonal contraception 26 27.1 10 24.4 16 29.1 0.377
Oral contraception 59 61.5 23 56.1 36 65.5 0.129
Contraceptive implant 7 7.3 5 12.2 2 3.6 0.041*
Dianette 5 5.2 4 9.8 1 1.8 0.020*
Kind of ADR mentioned in the link
Depression 69 71.9 25 61.0 44 80.0 0.005**
Mood changes/swings 36 37.5 21 51.2 15 27.3 0.002**
Mood/moody 14 14.6 6 14.6 8 14.5 0.907
Kind of association of the link
Statement 41 42.7 26 63.4 15 27.3 0.000**
Statement with scientific reference 39 40.6 6 14.6 33 60.0 0.000**
Personal story 31 32.3 16 39.0 15 27.3 0.105
Number of newspaper articles that (indirectly) referred to the Skovlund et al paper
30 54.5
aFisher's exact test.
*Statistically significant at the 0.05 level,
**Statistically significant at the 0.01 level.
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( χ2 (1) = 22.088, P < 0.01), whereas using a statement backed by
scientific reference increased after September 2016 (n = 33, 60.0%)
compared to before September 2016 (n = 6, 14.6%) ( χ2
(1) = 41.056, P < 0.01).
The inter-rater reliability for articles (n = 14, 14.5%) coded by LP
and PD is shown in Table 2.
3.2 | ADR reports of hormonal contraceptives
The age distribution of ADR reports within the HLGT
Depressed mood disorders and disturbances and all ADR reports for
hormonal contraception between 2014 and 2017 is shown in
Figure 4.
F IGURE 2 Flowchart of included and
excluded newspaper articles found with the
search terms in the databases ProQuest and
LexisNexis
F IGURE 3 Number of
relevant newspaper articles by
month
F IGURE 1 Prescribed items
of combined contraceptives and
progestogen-only contraceptives
by month. *Statistically significant
at the 0.05 level, **statistically
significant at the 0.01 level
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3.2.1 | Monthly ADR reports for depressed mood
disorders and disturbances before and after
September 2016
There was a statistically significant increase in the number of ADR
reports/100 000 000 items sent to the MHRA linking combined con-
traceptives with Depressed mood disorders and disturbances in January-
April 2017 compared to the same 4 months in the previous 3 years (F
(3, 15) = 4.545, 0.024), shown in Figure 5. Levene's test indicated no
violation of the assumption of homogeneity (P > 0.05) and therefore
the Bonferroni post hoc test was used to locate the difference, which
was between the number of reports submitted in the first 4 months of
2017 versus the first 4 months of 2014 (P < 0.05). No such difference
was found at all for reports relating to progestogen-only contracep-
tives (F(3, 15) = 0.882, 0.478). In addition, no differences were found
between the respective reports submitted in September-December
2016 compared to the same 4 months in 2014, 2015 and 2017,
either for combined contraceptives (F(3, 15) = 0.591, 0.633) or for
progestogen-only contraceptives (F(3, 15) = 1.307, 0.317). Finally,
reports submitted for combined contraceptives (rs = 0.690, P = 0.058)
and progestogen-only contraceptives (rs = −0.238, P = 0.570)
remained stable between September 2016 and April 2017.
3.2.2 | Women versus HCP ADR reports for
hormonal contraceptives
There was an increase in all ADR reports for combined contraceptives
between 2016 and 2017 whether submitted by women
(2621/100 000 000 items vs 3397/100 000 000 items) or health pro-
fessionals (1577/100 000 000 items vs 1846/100 000 000 items),
with a similar pattern for all ADR reports for progestogen-only contra-
ceptives submitted by women (3999/100 000 000 items vs
4286/100 000 000 items) but not health professionals. Women were
generally more likely to have reported an ADR per se for a combined
contraceptive than health professionals (65:35), whereas this figure
was around 50:50 for progestogen-only contraceptives (see Figure 6).
Nearly all of the reports linking combined contraceptives with
Depressed mood disorders and disturbances were made by women, with
the figure being 9:1 for progestogen-only contraceptives. The wider
trend across the four study years is shown in Figure 5. In addition,
there was a statistically significant increase in the number of women
reports linking combined contraceptives (but not progestogen-only
contraceptives) with Depressed mood disorders and disturbances
between 2016 (394/100 000 000 items) and 2017 (960/100 000 000
items) ( χ2 (1) = 10.185, P < 0.01).
4 | DISCUSSION
While the number of newspaper articles mentioning contraception
and depression or mood changes in the 4 months following the publi-
cation of the Skovlund et al paper1 did not significantly increase, the
number of headlines that mentioned both themes after September
2016 did increase, and more articles published after this time also
focused on the causative relationship between the two as the major
theme in the body of the article, backed by reference to science. The
overall reporting of all ADRs by both women and HCPs also increased
between 2016 and 2017 for both drug categories. However, for the
category of combined contraceptives this increase was due to reports
by women of Depressed mood disorders and disturbances in 2017, while
this was not the case for the progestogen-only contraceptives. This
increase in reports by women for the combined contraceptives
occurred predominantly in the first 4 months of 2017, suggestive of a
lag period between the publication of the Skovlund et al paper and
the reporting of depression or mood-related ADRs by women.1 A final
observation was that the vast majority of ADR reports relating to
Depressed mood disorders and disturbances in general for both types of
hormonal contraception were made by women rather than HCPs.
This study suggests media reporting of the link between hor-
monal contraception and depression or mood changes increases ADR
reports by women relating to combined contraceptives. The frames of
the newspaper stories changed from being mainly focussed on female
contraception to mainly focussing on the link between hormonal con-
traceptives and depression or mood, while giving scientific references
to studies mentioning this link.1 This suggests that if there is an effect
on patient reporting of ADRs, it is the frame in which the stories are
presented rather than the quantity of media attention which acts as
the causative agent.
Monthly data on Depressed mood disorders and disturbances
showed an increase in ADR reports of this subset for combined con-
traceptives in January-April 2017 compared to the same months in
2014. This, in combination with the fact that ADR reports did not
increase in September-December 2016, suggests a lag time between
the publication of the Skovlund et al paper,1 the heightened media
attention and actual ADR reporting by women. This lag time is not in
line with the findings of Martin et al and Van Hunsel et al.6,8 Their
results show a short peak in ADR reports of respectively paroxetine
and statins directly after the media coverage about these drugs. An
explanation of the lag time in this study could be that the media cov-
erage in newspapers here did not show a peak after publication of the
Skovlund et al paper1 and was spread over a couple of months, which
could have led to the lag time in ADR reports.
Overall, an increase in ADR reports by women was seen for all
hormonal contraceptives when comparing 2016 to 2017, suggesting
TABLE 2 Inter-rater reliability of content analysis
Category Cohen's kappa Level of agreement
Theme of the article 0.898 Strong
Contraception method 0.886 Strong
Side effect 0.770 Moderate
Association 0.891 Strong
Skovlund et al 1.000 Perfect
Value of κ (level of agreement) = 0.0-0.20 (none), 0.21-0.39 (minimal),
0.40-0.59 (weak), 0.60-0.79 (moderate), 0.80-0.90 (strong), >0.90 (almost
perfect).27
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women were generally more aware of the possibility to report ADRs
themselves. This is in line with the findings of a study by Banovac
et al, who found that women were more likely to report ADRs for hor-
monal indications than HCPs and reports by women were expected to
increase more over time.28 The increase in ADR reports for combined
contraceptives was because of a significant increase in the reporting
of Depressed mood disorders and disturbances by women. This finding
could suggest that women using combined contraceptives were more
F IGURE 5 Monthly ADR reports of the HLGT depressed mood disorders and disturbances
(A)
(B)
F IGURE 4 (A) Age distribution of HLGT
depressed mood disorders and disturbances
reports for hormonal contraceptives between
2014 and 2017. (B) Age distribution of all ADR
reports for hormonal contraceptives between
2014 and 2017
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likely to show agency and take it upon themselves to report
these ADRs.
A notable difference was seen in the proportions of ADR reports
by women versus HCPs for combined contraceptives and
progestogen-only contraceptives when comparing all ADR reports
and the reports for Depressed mood disorders and disturbances. The
vast majority of reports for the subset was made by women. De
Langen et al showed that depression is in the top 10 most frequently
reported ADRs by patients, but is absent in the list of ADRs reported
by HCPs.29 Another finding of De Langen et al is that HCPs do not
take a suspected ADR seriously in 50% of the cases and did not want
to report the ADR. A possible explanation for the difference in pro-
portions for all ADRs and ADRs of Depressed mood disorders and
disturbances could be therefore that HCPs do not take the suspected
ADR seriously because of the psychiatric nature of depression and,
therefore, women had to report the ADRs themselves.
This study has several strengths and limitations. The main
strengths of this study are the long time period in which newspaper
articles, prescription items and ADR reports are compared, and that a
comparison is not only made between the number of articles before
and after publication of the Skovlund et al paper,1 but also between
the content of the newspaper articles, with data on combined contra-
ceptives and progestogen-only contraceptives analysed separately.
The data showing the monthly numbers of ADR reports for depressed
mood disorders and disturbances are somewhat overestimated in this
study because it was not possible to exclude some reports relating to
other hormone treatments such as emergency oral contraception, and
no distinction could be made between women and HCPs for these
reports. This limitation arose due to lack of 1B data for this category
of ADR reports received directly from the MHRA. Therefore, the
short-term effects of heightened media attention, as suggested by
Hernandez et al, Van Hunsel et al and Martin et al, could not be
examined for women and HCPs separately.6,8 Nonetheless, it was
possible to compare women vs HCP reports in the year that followed
the publication of Skovlund et al paper to the year before.1
5 | CONCLUSION
Heightened media attention after publication of the Skovlund et al
paper1 in September 2016 appears to have increased the number of
ADR reports linking combined contraceptives with Depressed mood
disorders and disturbances submitted to the MHRA in the following
quarter (January-April 2017). The framing of the news story, and not
necessarily the quantity of media attention, is likely to have led to the
effect on women reporting ADRs for combined contraceptives. No
effect was shown for the reporting of ADRs for progestogen-only
contraceptives. A difference was shown in the proportions of reports
by women and HCPs for Depressed mood disorders and disturbances
compared to all ADRs. These findings confirm that HCPs and
regulatory agencies can expect an increase in patient awareness of
ADRs after media attention prompting them to respond to this by
guiding patients at the time. Further research is necessary to examine
the attitude of HCPs towards depression or mood changes as ADRs
of hormonal contraceptives.
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